Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Atenolol

Generic name
Atenolol
Brand name
ATC Code
C07AB03

Pharmacokinetics in children

The elimination half-life in children older than 5 years is on average between 3.5 and 7 hours [Buck et al.]. In neonates it is between 10.5 and 34.6 hours [Rubin et al.].

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Hypertension, supraventricular arrhythmias, Marfan syndrome
  • Oral
    • 1 month up to 18 years
      • Initial dose: 0.5 - 1 mg/kg/day in 1 - 2 doses.
      • Maintenance dose: Depending on the haemodynamic response, the initial dose can be raised to 1 - 4 mg/kg/day in 1 - 2 doses. Max: 250 mg/day.
Haemangiomas
  • Oral
    • 1 month up to 14 months
      • 1 mg/kg/day in 1 dose

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

Adjustment in renal impairment as specified:

GFR 50-80 ml/min/1.73 m2
Adjustment not necessary.
GFR 30-50 ml/min/1.73 m2
Adjustment not necessary.
GFR 10-30 ml/min/1.73 m2
50 percentage of single dose and dosing interval : 12 up to 24 uur
GFR < 10 ml/min/1.73 m2
Generalized recommendations cannot be given

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Dyspnoea, cold extremities, provocation of congestive heart failure or hypoglycaemia (without symptoms: take care with diabetes patients) and nightmares. Few central side effects.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications in children

Sinus bradycardia, AV block, hypotension and asthma.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Great caution is needed in concomitant use of verapamil (Isoptin) because of the risk of arrhythmia. In cases of hypertension, start with a low dose and increase it depending on the blood pressure. Try to halve the dose after six months’ success. Always phase the dosage out slowly.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Beta blocking agents, non-selective
C07AA05
C07AA07
Beta blocking agents, selective
C07AB07
C07AB09
C07AB02
Alpha and beta blocking agents
C07AG02
C07AG01

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents., The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents., Pediatrics, 2004, Aug;114(2 Suppl 4th Report), 555-76
  3. Ko JK, et al, Long-term efficacy of atenolol for atrioventricular reciprocating tachycardia in children less than 5 years old, Pediatr Cardiol, 2004, Mar-Apr;25(2), 97-101
  4. Mehta AV, et al, Long-term efficacy and safety of atenolol for supraventricular tachycardia in children, Pediatr Cardiol, 1996, Jul-Aug;17(4), 231-6
  5. Trippel DL, et al, Atenolol in children with ventricular arrhythmias, Am Heart J, 1990, Jun;119(6), 1312-6
  6. Buck ML, et al, Pharmacokinetics and pharmacodynamics of atenolol in children, Clin Pharmacol Ther., 1989, Dec;46(6, 629-33
  7. Trippel DL, et al, Atenolol in children with supraventricular tachycardia, Am J Cardiol, 1989, Jul 15;64(3), 233-6
  8. Rubin PC, et al, Atenolol elimination in the neonate, Br J Clin Pharmacol, 1983, Dec;16(6), 659-62
  9. Lacro RV et al., Atenolol versus losartan in children and young adults with Marfan’s syndrome, N Eng J Med, 2014, Nov;371(22), 2061-71
  10. Ábarzúa-Araya A, et al, Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study, J Am Acad Dermatol, 2014, Jun;70(6), 1045-9
  11. Raphaël MF, et al, Atenolol: a promising alternative to propranolol for the treatment of hemangiomas., J Am Acad Dermatol, 2011, 2011, Aug;65(2), 420-1
  12. Lurbe E, et al, Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension, J Hypertens, 2009, Sep;27(9),, 1719-42
  13. Ruitenberg G et al, Ulcerated infantile haemangiomas: the effect of the selective beta-blocker atenolol on wound healing, Br J Dermatol, 2016, 175, 1357-1360
  14. Di Salvo G, et al., Atenolol vs enalapril in young hypertensive patients after successful repair of aortic coarctation, J Hum Hypertens, 2016, 30, 363-7
  15. Bayart CB, et al., Atenolol versus propranolol for treatment of infantile hemangiomas during the proliferative phase: a retrospective noninferiority study, Pediatr Dermatol, 2017, 34, 413-21
  16. Tasani M, et al., Atenolol treatment for infantile haemangioma, Br J Dermatol, 2017, 176, 1400-2
  17. Calderón-Castrat X, et al., Oral Atenolol for Infantile Hemangioma: Case Series of 46 Infants., Actas Dermosifiliogr, 2020, 111(1), 59-62

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes